Option Care Health, Inc.

Option Care Health, Inc. Earnings Recaps

OPCH Health Care 3 recaps
Q1 2026 May 2, 2026

Option Care Health shares fell 25.5% after first quarter results, as investors reacted to a revenue growth deceleration and a downward revision to full-year revenue guidance stemming from an unexpected drop in the chronic therapy patient census and delayed program launches.

Key takeaways
  • Reported revenue growth of just 1% for Q1, below company expectations, with chronic therapy revenues declining year-over-year.
  • Acute therapy portfolio delivered high single-digit revenue growth, outperforming market growth rates.
  • Chronic portfolio faced headwinds including a "significantly higher" number of patients affected by insurance changes, causing patient census to fall more than anticipated and leading to a less favorable therapy mix.
  • Guidance for full-year revenue was revised down due to more challenging industry dynamics, regulatory or commercial delays in rare/orphan portfolio launches, and slower-than-expected growth in specialty therapies.
  • Management is reallocating resources, increasing commercial team size, and refocusing growth initiatives in response to these challenges.
Full recap
Q3 2025 Oct 31, 2025

Option Care Health reported strong third-quarter performance with a 12% revenue growth, driven by solid contributions from both acute and chronic therapy segments, while making strategic leadership changes to enhance operational efficiency.

Key takeaways
  • Revenue increased by 12% year-over-year, significantly outpacing industry growth rates.
  • Acute therapy revenue growth reached the mid-teens, bolstered by a favorable competitive landscape.
  • Continued expansion of nursing services, with over 175,000 visits conducted in the quarter, demonstrating efficiency in care delivery.
  • New partnerships with pharmaceutical manufacturers enhance clinical capabilities and expand the therapy portfolio.
  • Adjusted 2025 full-year revenue and EBITDA forecasts raised, reflecting ongoing operational strength and favorable market conditions.
Full recap
Q2 2025 Jul 30, 2025

Option Care Health delivered a robust second quarter, achieving a 15% year-over-year revenue growth, leading to an upward revision of revenue, adjusted EBITDA, and adjusted EPS guidance for the year.

Key takeaways
  • Revenue increased 15% year-over-year, driven by strong performance in both acute and chronic therapy segments.
  • Adjusted EBITDA grew by 5% despite headwinds, underscoring operational efficiency and disciplined spending.
  • Generated over $90 million in cash flow from operations, positioning the company for ongoing capital deployment and shareholder value initiatives.
  • Successful partnerships with health plans and pharma manufacturers enhance access to tailored therapies, supporting growth in rare and orphan drugs.
  • Executed $50 million in share repurchases during the quarter, reflecting confidence in long-term business potential and shareholder value creation.
Full recap